Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 901–1,000 of 4,628
Patel, A. S., Miller, E. R., Regis, S. M., Hunninghake, G. M., Price, L. L., Gawlik, M., McKee, A. B., Rieger‐Christ, K., Pinto-Plata, V., Liesching, T. N., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02359-9 · Cited by 48
Personalized medicine in idiopathic pulmonary fibrosis: facts and promises
Spagnolo, P., Tzouvelekis, A., & Maher, T. M. (2015) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000187 · Cited by 46
Therapeutic Approach to Adult Fibrotic Lung Diseases
Adegunsoye, A., & Strek, M. E. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.07.027 · Cited by 52
Otsubo, K., Kishimoto, J., Kenmotsu, H., Minegishi, Y., Ichihara, E., Shiraki, A., Kato, T., Atagi, S., Horinouchi, H., Ando, M., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.06.003 · Cited by 50
Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions
Ferrara, G., Luppi, F., Birring, S. S., Cerri, S., Caminati, A., Sköld, M. C., & Kreuter, M. (2018) · European Respiratory Review · doi:10.1183/16000617.0076-2017 · Cited by 49
The increasing mortality of idiopathic pulmonary fibrosis: fact or fallacy?
Ryerson, C. J., & Kolb, M. R. J. (2018) · European Respiratory Journal · doi:10.1183/13993003.02420-2017 · Cited by 51
Self-citationPiñol‐Jurado, P., Suárez‐Calvet, X., Fernández‐Simón, E., Gallardo, E., de la Oliva, N., Martínez‐Muriana, A., Gómez‐Gálvez, P., Escudero, L. M., Pérez-Peiró, M., Wollin, L., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0792-6 · Cited by 50
Shochet, G. E., Brook, E., Eyal, O., Edelstein, E., & Shitrit, D. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00526.2018 · Cited by 52
“Nintedanib (OFEV), which is an approved drug for the treatment of IPF (26), has shown consistent anti-fibrotic and anti-inflammatory activity (37).”
BackgroundWollin, L., Distler, J. H. W., Denton, C. P., & Gahlemann, M. (2019) · Journal of Scleroderma and Related Disorders · doi:10.1177/2397198319841842 · Cited by 47
Kreuter, M., Kögler, H., Trampisch, M., Geier, S., & Richeldi, L. (2019) · Respiratory Research · doi:10.1186/s12931-019-1037-7 · Cited by 49
Self-citationFukihara, J., Kondoh, Y., Brown, K. K., Kimura, T., Kataoka, K., Matsuda, T., Yamano, Y., Suzuki, A., Furukawa, T., Sumikawa, H., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02465-2018 · Cited by 49
Self-citationGulati, S., & Luckhardt, T. (2020) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s224007 · Cited by 48
Maher, T. M., Mayes, M. D., Kreuter, M., Volkmann, E. R., Aringer, M., Castellvi, I., Cutolo, M., Stock, C., Schoof, N., Alves, M., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41576 · Cited by 49
Self-citationKnipe, R. S., Spinney, J. J., Abe, E. A., Probst, C. K., Franklin, A., Logue, A., Giacona, F., Drummond, M., Griffith, J., Brazee, P. L., et al. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0408oc · Cited by 55
Guler, S. A., Hur, S. A., Stickland, M. K., Brun, P., Bovet, L., Holland, A. E., Bondarenko, J., Hambly, N., Wald, J., Makhdami, N., et al. (2021) · Thorax · doi:10.1136/thoraxjnl-2021-217361 · Cited by 48
Xu, J., Wang, P., Yang, H. J., Zhou, J., Li, Y., Li, X., Xue, W., Yu, C., Tian, Y., & Zhu, F. (2016) · BioMed Research International · doi:10.1155/2016/2509385 · Cited by 47
Majewski, S., Szewczyk, K., Żal, A., Białas, A. J., Miłkowska-Dymanowska, J., & Piotrowski, W. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173864 · Cited by 53
Tissue mechanics coevolves with fibrillar matrisomes in healthy and fibrotic tissues
Dooling, L. J., Saini, K., Anlaş, A. A., & Discher, D. E. (2022) · Matrix Biology · doi:10.1016/j.matbio.2022.06.006 · Cited by 46
GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial
Strambu, I. R., Seemayer, C. A., Fagard, L., Ford, P., Aa, T. V. D., de Haas, A., Modgill, V., Santermans, E., Sondag, E., Helmer, E., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.01794-2022 · Cited by 53
Self-citationNovel inhalation therapy in pulmonary fibrosis: principles, applications and prospects
Zheng, M., Zhu, W., Gao, F., Zhuo, Y., Mo, Z., Wu, G., & Feng, C. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02407-6 · Cited by 56
Acute exacerbations in patients with idiopathic pulmonary fibrosis
Kim, D. W. (2013) · Respiratory Research · doi:10.1186/1465-9921-14-86 · Cited by 49
Self-citation17(R)-resolvin D1 ameliorates bleomycin-induced pulmonary fibrosis in mice
Yatomi, M., Hisada, T., Ishizuka, T., Koga, Y., Ono, A., Kamide, Y., Seki, K., Aoki‐Saito, H., Tsurumaki, H., Sunaga, N., et al. (2015) · Physiological Reports · doi:10.14814/phy2.12628 · Cited by 50
Ryerson, C. J., Camp, P. G., Eves, N. D., Schaeffer, M. R., Syed, N., Dhillon, S. S., Jensen, D., Maltais, F., O’Donnell, D. E., Raghavan, N., et al. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201604-267oc · Cited by 48
Self-citationGreater cellular stiffness in fibroblasts from patients with idiopathic pulmonary fibrosis
Jaffar, J., Yang, S.-H., Kim, S. Y., Kim, H., Faiz, A., Chrzanowski, W., & Burgess, J. K. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00030.2018 · Cited by 51
“The mechanisms governing fibroblast behavior in fibrotic lung disease are not fully understood, consequently current treatments have limited efficacy to prevent, or reverse, the fibrotic process (14, 25, 26).”
BackgroundUnderstanding the patient's experience of care in idiopathic pulmonary fibrosis
Burnett, K., Glaspole, I., & Holland, A. E. (2018) · Respirology · doi:10.1111/resp.13414 · Cited by 44
Pulmonary Complications of Rheumatoid Arthritis
Farquhar, H. J., Vassallo, R., Edwards, A. L., & Matteson, E. L. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1683995 · Cited by 56
Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases
Liu, F., Bayliss, G. P., & Zhuang, S. (2019) · Clinical Science · doi:10.1042/cs20190249 · Cited by 52
“In clinical trials, nintedanib was effective in improving lung function in patients with IPF, reducing acute attack frequency and improving patient quality of life [18, 19].”
BackgroundMethodInfluentialNoth, I., Wijsenbeek, M. S., Kolb, M. R. J., Bonella, F., Moros, L., Wachtlin, D., & Corte, T. J. (2019) · European Respiratory Journal · doi:10.1183/13993003.01797-2018 · Cited by 47
Self-citationNintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Distler, O., Gahlemann, M., & Maher, T. M. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1910735 · Cited by 46
Biondini, D., Balestro, E., Sverzellati, N., Cocconcelli, E., Bernardinello, N., Ryerson, C. J., & Spagnolo, P. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1724096 · Cited by 51
“Nintedanib and pirfenidone Recent data suggest that nintedanib may reduce the risk of developing an AE-IPF as well as mortality following the acute event [18,62,63].”
BackgroundNintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis
Keating, G. M. (2015) · Drugs · doi:10.1007/s40265-015-0418-6 · Cited by 49
Nikitopoulou, I., Manitsopoulos, N., Kotanidou, A., Tian, X., Petrovic, A., Magkou, C., Ninou, I., Aidinis, V., Schermuly, R. T., Kosanovic, D., et al. (2019) · Pulmonary Circulation · doi:10.1177/2045894019881954 · Cited by 44
“Several multicenter clinical trials have been conducted for IPF, but only two drugs (pirfenidone and nintedanib) were proved to be effective as disease-modifying therapies.(5) However, for a number of patients the only effective treatment will still be lung transplantation.”
BackgroundTeague, T., Payne, S. R., Kelly, B. T., Dempsey, T. M., McCoy, R. G., Sangaralingham, L. R., & LIMPER, A. H. (2022) · Respiratory Research · doi:10.1186/s12931-022-02001-0 · Cited by 56
Podolanczuk, A. J., Kim, J. S., Cooper, C. B., Lasky, J. A., Murray, S., Oldham, J. M., Raghu, G., Flaherty, K. R., Spino, C., Noth, I., et al. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-02281-8 · Cited by 52
Self-citationThe Future of Lung Transplantation
Nathan, S. D. (2015) · CHEST Journal · doi:10.1378/chest.14-1748 · Cited by 49
Ambulatory and short-burst oxygen for interstitial lung disease
Sharp, C., Adamali, H. I., & Millar, A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011716.pub2 · Cited by 44
Dasatinib attenuated bleomycin-induced pulmonary fibrosis in mice
Yilmaz, O., Öztay, F., & Kayalar, Ö. (2015) · Growth Factors · doi:10.3109/08977194.2015.1109511 · Cited by 46
Mortality and Respiratory Failure After Thoracoscopic Lung Biopsy for Interstitial Lung Disease
Durheim, M. T., Kim, S., Gulack, B. C., Burfeind, W. R., Gaissert, H. A., Kosinski, A. S., & Hartwig, M. G. (2017) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2017.02.013 · Cited by 46
Ikeda, S., Sekine, A., Baba, T., Yamanaka, Y., Sadoyama, S., Yamakawa, H., Oda, T., Okuda, R., Kitamura, H., Okudela, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11321-x · Cited by 44
Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential
Raghu, G. (2017) · European Respiratory Review · doi:10.1183/16000617.0071-2017 · Cited by 45
Self-citationRamadurai, D., Corder, S., Churney, T., Graney, B. A., Harshman, A., Meadows, S. K., & Swigris, J. J. (2018) · BMJ Open Quality · doi:10.1136/bmjoq-2017-000207 · Cited by 48
Wilfong, E. M., Lentz, R. J., Guttentag, A. R., Tolle, J., Johnson, J. E., Kropski, J. A., Kendall, P. L., Blackwell, T. S., & Crofford, L. J. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40679 · Cited by 51
“Conversely, patients with IPF benefit from antifibrotic agents such as nintedanib (5) and pirfenidone (6), but these drugs are not approved for use in CTDassociated ILD.”
BackgroundTreating Heart Failure with Preserved Ejection Fraction: Learning from Pulmonary Fibrosis
Graziani, F., Varone, F., Crea, F., & Richeldi, L. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1286 · Cited by 44
Self-citationDiagnosis of Idiopathic Pulmonary Fibrosis: Differential Diagnosis
Aburto, M., Herráez, I., Fernandez, D. I., & Jiménez-Romero, A. I. (2018) · Medical Sciences · doi:10.3390/medsci6030073 · Cited by 58
“In patients with a possible UIP CT pattern, it has been observed that the disease progresses the same way as in patients with a UIP CT pattern treated with the same antifibrotic [25,26].”
ResultLung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis
Brown, K. K., Flaherty, K. R., Cottin, V., Raghu, G., Inoue, Y., Azuma, A., Huggins, J. T., Richeldi, L., Stowasser, S., Stansen, W., et al. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2018.11.012 · Cited by 44
Self-citationArish, N., Petukhov, D., & Wallach‐Dayan, S. B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122996 · Cited by 47
Connective Tissue Disease Related Interstitial Lung Disease
Schulte, J. J., & Husain, A. N. (2020) · Surgical pathology clinics · doi:10.1016/j.path.2019.11.005 · Cited by 46
Inhibition of Aurora Kinase B attenuates fibroblast activation and pulmonary fibrosis
Kasam, R. K., Ghandikota, S. K., Soundararajan, D., Reddy, G. B., Huang, S. K., Jegga, A. G., & Madala, S. K. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012131 · Cited by 50
“However, neither of these drugs provide a cure, and both of them are associated with several serious drug-related side effects (King et al, 2014; Richeldi et al, 2014; Hughes et al, 2016).”
BackgroundVEGFR1-tyrosine kinase signaling in pulmonary fibrosis
Amano, H., Matsui, Y., Hatanaka, K., Hosono, K., & Ito, Y. (2021) · Inflammation and Regeneration · doi:10.1186/s41232-021-00166-7 · Cited by 49
Ryerson, C. J., Corte, T. J., Myers, J. L., Walsh, S. L. F., & Guler, S. A. (2021) · European Respiratory Journal · doi:10.1183/13993003.00276-2021 · Cited by 47
Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?
Ratain, M. J., Tannock, I. F., & Lichter, A. S. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01371 · Cited by 46
Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
Costabel, U., Albera, C., Glassberg, M. K., Lancaster, L. H., Wuyts, W. A., Petzinger, U., Gilberg, F., Kirchgaessler, K.-U., & Noble, P. W. (2019) · Respiratory Research · doi:10.1186/s12931-019-1021-2 · Cited by 43
Self-citationDiagnosing interstitial lung disease by multidisciplinary discussion: A review
Glenn, L. M., Troy, L. K., & Corte, T. J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1017501 · Cited by 50
Walsh, S. L. F., Backer, J. D., Prosch, H., Langs, G., Calandriello, L., Cottin, V., Brown, K. K., Inoue, Y., Tzilas, V., & Estes, E. A. (2024) · European Respiratory Review · doi:10.1183/16000617.0055-2023 · Cited by 52
Self-citationUrushiyama, H., Terasaki, Y., Nagasaka, S., Terasaki, M., Kunugi, S., Nagase, T., Fukuda, Y., & Shimizu, A. (2015) · Laboratory Investigation · doi:10.1038/labinvest.2015.66 · Cited by 46
Interstitial Lung Disease Evaluation: Detecting Connective Tissue Disease
Fischer, A., Lee, J. S., & Cottin, V. (2015) · Respiration · doi:10.1159/000440665 · Cited by 46
Self-citationBill, R., Fagiani, E., Zumsteg, A., Antoniadis, H., Johansson, D., Haefliger, S., Albrecht, I., Hilberg, F., & Christofori, G. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3036 · Cited by 44
Adegunsoye, A., & Balachandran, J. S. (2015) · Mediators of Inflammation · doi:10.1155/2015/510105 · Cited by 46
Smoking-Related Interstitial Lung Disease
Hagmeyer, L., & Randerath, W. J. (2015) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2015.0043 · Cited by 55
Novel drug targets for idiopathic pulmonary fibrosis
Sgalla, G., Cocconcelli, E., Tonelli, R., & Richeldi, L. (2016) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2016.1152186 · Cited by 42
Self-citationFerrara, G., Carlson, L., Palm, A., Einarsson, J., Olivesten, C., Sköld, M., & Pulmonar, F. T. S. I. (2016) · European Clinical Respiratory Journal · doi:10.3402/ecrj.v3.31090 · Cited by 43
Adegunsoye, A., Hrusch, C. L., Bonham, C. A., Jaffrey, M. R., Blaine, K. M., Sullivan, M., Churpek, M. M., Strek, M. E., Noth, I., & Sperling, A. I. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00516 · Cited by 48
Kishaba, T., Nagano, H., Nei, Y., & Yamashiro, S. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.12.49 · Cited by 47
Guidelines for the Medical Treatment of Idiopathic Pulmonary Fibrosis
Xaubet, A., Molina‐Molina, M., Acosta, O., Bollo, E., Castillo, D., Fernández‐Fabrellas, E., Rodríguez-Portal, J. A., Valenzuela, C., & Ancochea, J. (2017) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2017.03.001 · Cited by 49
Cell‐specific expression of runt‐related transcription factor 2 contributes to pulmonary fibrosis
Mümmler, C., Burgy, O., Hermann, S., Mutze, K., Günther, A., & Königshoff, M. (2017) · The FASEB Journal · doi:10.1096/fj.201700482r · Cited by 51
Clay, R., Bartholmai, B. J., Zhou, B., Karwoski, R. A., Peikert, T., Osborn, T. G., Rajagopalan, S., Kalra, S., & Zhang, X. (2018) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000334 · Cited by 48
Flaherty, K. R., Kolb, M., Vancheri, C., Tang, W., Conoscenti, C. S., & Richeldi, L. (2018) · European Respiratory Journal · doi:10.1183/13993003.02593-2017 · Cited by 43
Self-citationBarratt, S. L., Mulholland, S., Al Jbour, K., Steer, H., Gutsche, M., Foley, N., Srivastava, R., Sharp, C., & Adamali, H. I. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01480 · Cited by 43
Management of Fibrosing Interstitial Lung Diseases
Maher, T. M., & Wuyts, W. A. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00992-9 · Cited by 48
“Nintedanib has been shown to slow lung function decline and reduce the risk of acute exacerbations in patients with IPF, with side effects that are mainly gastrointestinal [71, 72].”
BackgroundWatanabe, N., Niho, S., Kirita, K., Umemura, S., Matsumoto, S., Yoh, K., Ohmatsu, H., & Goto, K. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2775-y · Cited by 45
Surber, M. W., Beck, S., Pham, S., Marsden, A. T., Gandi, S. K., Baily, J. E., & McElroy, M. (2020) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2020.101938 · Cited by 45
“One phase 2 and two phase 3 IPF registration trials confirmed that oral nintedanib reduced annual forced vital capacity (FVC) decline [8,9].”
BackgroundToda, M., Mizuguchi, S., Minamiyama, Y., Yamamoto-Oka, H., Aota, T., Kubo, S., Nishiyama, N., Shibata, T., & Takemura, S. (2018) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.17-111 · Cited by 42
Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis
King, C. S., & Nathan, S. D. (2015) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000190 · Cited by 44
Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra
Rajagopal, K., Bryant, A. J., Sahay, S., Wareing, N. E., Zhou, Y., Pandit, L. M., & Karmouty‐Quintana, H. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15036 · Cited by 51
“Conversely, antifibrotic drug trials (see above) have excluded patients with advanced IPF and/or PH (King et al., 2014; Noble et al., 2011; Richeldi et al., 2014).”
BackgroundMummy, D. G., Bier, E. A., Wang, Z., Korzekwinski, J., Morrison, L. D., Barkauskas, C. E., McAdams, H. P., Tighe, R. M., Driehuys, B., & Mammarappallil, J. G. (2021) · Radiology · doi:10.1148/radiol.2021204149 · Cited by 42
Tsitoura, E., Trachalaki, A., Vasarmidi, E., Mastrodemou, S., Margaritopoulos, G. A., Kokosi, M. A., Fanidis, D., Galaris, A., Aidinis, V., Renzoni, E. A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.645548 · Cited by 46
“Treatment with Nintedanib, a novel antifibrotic that changed the landscape in IPF treatment (42, 43), has similar efficacy in other PF-ILDs (44, 45), as well as in SSc-ILD (46).”
ResultJi, K., Fan, M., Huang, D., Sun, L., Li, B., Xu, R., Zhang, J., Shao, X., & Chen, Y. (2022) · Biomaterials Science · doi:10.1039/d1bm01663f · Cited by 41
Pergolizzi, J. V., LeQuang, J. A., Varrassi, M., Breve, F., Magnusson, P., & Varrassi, G. (2023) · Advances in Therapy · doi:10.1007/s12325-022-02395-9 · Cited by 47
Xie, Y., Lin, Y., Shi, Y., Su, X., Gan, C., Liu, H., Xue, T., & Ye, T. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01753 · Cited by 53
Juge, P., Hayashi, K., McDermott, G. C., Vanni, K. M. M., Kowalski, E., Qian, G., Bade, K. J., Saavedra, A. A., Dieudé, P., Dellaripa, P. F., et al. (2023) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2023.152312 · Cited by 46
Lederer, D. J., Bradford, W. Z., Fagan, E., Glaspole, I., Glassberg, M. K., Glasscock, K., Kardatzke, D. R., King, T. E., LANCASTER, L. H., Nathan, S. D., et al. (2015) · CHEST Journal · doi:10.1378/chest.14-2817 · Cited by 43
Self-citationChung, J. H., & Lynch, D. A. (2016) · American Journal of Roentgenology · doi:10.2214/ajr.15.15627 · Cited by 47
“Food and Drug Administration for the treatment of IPF after they were shown to slow the decline in pulmonary function over time, which has renewed interest in the accurate diagnosis of IPF [1–3].”
Background“Scar-cinoma”: viewing the fibrotic lung mesenchymal cell in the context of cancer biology
Horowitz, J. C., Osterholzer, J. J., Marazioti, A., & Stathopoulos, G. T. (2016) · European Respiratory Journal · doi:10.1183/13993003.01201-2015 · Cited by 45
McMillan, D. H., van der Velden, J. L. J., Lahue, K. G., Qian, X., Schneider, R. W., Iberg, M. S., Nolin, J. D., Abdalla, S. T., Casey, D. T., Tew, K. D., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.85717 · Cited by 44
Aiello, M., Bertorelli, G., Bocchino, M., Chetta, A. A., Fiore-Donati, A., Fois, A. G., Marinari, S., Oggionni, T., Polla, B., Rosi, E., et al. (2017) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2017.02.005 · Cited by 46
Discovery of BI-2545: A Novel Autotaxin Inhibitor That Significantly Reduces LPA Levels in Vivo
Kuttruff, C. A., Ferrara, M., Bretschneider, T., Hoerer, S., Handschuh, S., Nosse, B., Romig, H., Nicklin, P. L., & Roth, G. J. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00312 · Cited by 50
Update in Pulmonary Fibrosis 2018
Sgalla, G., Kulkarni, T., Antin-Ozerkis, D. E., Thannickal, V. J., & Richeldi, L. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201903-0542up · Cited by 43
Self-citationvan der Aar, E., Desrivot, J., Dupont, S., Heckmann, B., Fieuw, A. M., Stutvoet, S., Fagard, L., de Wal, K. V., & Helmer, E. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1424 · Cited by 43
Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?
Duitman, J., van den Ende, T., & Spek, C. A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101547 · Cited by 48
Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease
Kuwana, M., & Azuma, A. (2019) · Modern Rheumatology · doi:10.1080/14397595.2019.1696505 · Cited by 62
“In clinical trials with nintedanib in patients with IPF and SSc-ILD, the frequency of patients who experienced bleeding adverse events was slightly higher in the nintedanib than placebo arm [4,5].”
BackgroundResultInfluentialSelf-citationAnti-fibrotic mechanisms of exogenously-expanded mesenchymal stromal cells for fibrotic diseases
Rockel, J. S., Rabani, R., & Viswanathan, S. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.10.014 · Cited by 51
Kronborg-White, S. B., Andersen, C. U., Kohberg, C., Hilberg, O., & Bendstrup, E. M. (2020) · Respiratory Research · doi:10.1186/s12931-020-01452-7 · Cited by 43
Skibba, M. E., Drelich, A. J., Poellmann, M. J., Hong, S., & Brasier, A. R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.607689 · Cited by 49
“Therapeutics targeting the myofibroblast foci are therefore an exciting approach for treatment of ILDs.”
BackgroundGrześk, G., Woźniak-Wiśniewska, A., Błażejewski, J., Górny, B., Wołowiec, Ł., Rogowicz, D., & Nowaczyk, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010282 · Cited by 45
Liang, J., Cao, H., Yang, Y., Ke, Y., Yu, Y., Sun, C., Yue, L., & Lin, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.626953 · Cited by 50
“The therapeutic effect of nintedanib remain consistent irrespective of age, sex, ethnicity, and baseline percent-predicted forced vital capacity (FVC”
MethodInfluentialLiu, Y., Zhong, W., Zhang, J., Chen, W., Lu, Y., Qiao, Y., Zeng, Z., Huang, H., Zou, F., 孟小晶, et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.739220 · Cited by 46
“Previous studies using lung biopsies from IPF patients reported a diminution of autophagy (Patel et al., 2012; Araya et al., 2013) and some from animal model illustrated that TGF-β1 could mediate dysfunction of the autophagy response during lung fibrosis (Sosulski et al., 2015).”
BackgroundInfluentialPCSK6 and Survival in Idiopathic Pulmonary Fibrosis
Oldham, J. M., Allen, R. J., Lorenzo-Salazar, J. M., Molyneaux, P. L., Ma, S., Joseph, C., Kim, J. S., Guillén‐Guío, B., Hernández-Beeftink, T., Kropski, J. A., et al. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202205-0845oc · Cited by 53
Self-citationGill, M. W., Murphy, B. J., Cheng, P. T. W., Sivaraman, L., Davis, M., & Lehman-McKeeman, L. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.115885 · Cited by 41
Guo, H., Sun, J., Zhang, S., Nie, Y., Zhou, S., & Zeng, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1205948 · Cited by 41
“Nintedanib significantly mitigated the risk of disease progression and also demonstrated a mortality-reducing benefit (Richeldi et al., 2014).”
BackgroundA novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung
Matsuhira, T., Nishiyama, O., Tabata, Y., Kaji, C., Kubota-Ishida, N., Chiba, Y., Sano, H., Iwanaga, T., & Tohda, Y. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173508 · Cited by 41
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.